XML 54 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 15, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 24, 2018
Sep. 25, 2017
USD ($)
May 26, 2017
USD ($)
Jul. 27, 2016
USD ($)
Apr. 30, 2016
USD ($)
Apr. 30, 2016
TWD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
Dec. 31, 2020
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Collaborative Agreements (Details) [Line Items]                            
Milestone payments royalty percentage                 12.00%          
Additional paid-in capital                 $ 40,751,807     $ 40,751,807    
Co-Dev agreement, description     the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                      
BHK Co-Development Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Milestone payments to BioLite in cash           $ 10,000,000   $ 31,649,000            
Description of payment settlement           ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Upfront cash payment           $ 1,000,000                
Percentage of payments under co-development agreement           10.00%                
Common stock newly issued, value           $ 10,000,000 $ 1,000,000              
Collaborative agreements, description                 In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.   In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.      
Co-Dev Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Percentage of payments under co-development agreement         50.00%                  
Company cash payments $ 3,000,000                          
Addition cash payment         $ 3,000,000                  
Additional paid-in capital                   $ 3,000,000        
Amount received from BriVision                   450,000        
Collaborative Arrangement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Percentage of payments under co-development agreement   50.00%                        
Common stock newly issued, value   $ 3,000,000                        
Company cash payments   $ 3,000,000                        
Licensing rights       $ 3,000,000                    
Research and development expense                   $ 3,000,000        
BioFirst Stock Purchase Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Amount received from BriVision                         $ 2,902,911 $ 3,000,000
Shares issued (in Shares) | shares                         414,702 428,571